Targeting neuroinflammation in Alzheimer’s disease: from mechanisms to clinical applications
Open accessThe DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease is characterized by sustained neuroinflammation leading to memory loss and cognitive decline. The past decade has witnessed tremendous efforts in Alzheimer's disease research; however, no effective treatment is available to prevent disease progression. An increasing body of evidence suggests that neuroinflammation plays an important role in Alzheimer's disease pathogenesis, alongside the classical pathological hallmarks such as misfolded and aggregated proteins (e.g., amyloid-beta and tau). Firstly, this review summarized the clinical and pathological characteristics of Alzheimer's disease. Secondly, we outlined key aspects of glial cell-associated inflammation in Alzheimer's disease pathogenesis and provided the latest evidence on the roles of microglia and astrocytes in Alzheimer's disease pathology. Then, we revealed the double-edged nature of inflammatory cytokines and inflammasomes in Alzheimer's disease. In addition, the potential therapeutic roles of innate immunity and neuroinflammation for Alzheimer's disease were also discussed through these mechanisms. In the final section, the remaining key problems according to the current research status were discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The amyloid cascade hypothesis put forward in the 1990s proposes that misfolded and aggregated amyloid-beta (Aβ) protein triggers the pathological hallmarks of AD, such as neuronal cell death and dementia (Hardy and Allsop, 1991; Hardy and Higgins, 1992).”
BackgroundZhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875 · cited 2×
“TREM2 signaling pathway TREM2 is a type I transmembrane receptor uniquely expressed in microglia (Zhang et al., 2014).”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 1×
“It is becoming increasingly clear that microglia do not just play a secondary role in AD processes but virtually contribute to neuron loss, synaptic dysfunction, and the buildup of neurotoxic proteins in the very early stages of AD (Leng and Edison, 2021).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“It has been shown that TREM2 recognizes the Aβ chaperone APOE in the AD brain and the lipids and Aβ released from damaged neurons (Guerreiro et al., 2013).”
BackgroundKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 1×
“Microglia in TREM2-deficient mice and patients with the TREM2 R47H mutation exhibit enhanced autophagy due to dysregulated mTOR signal transduction (Krasemann et al., 2017).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“It has been shown that TREM2 recognizes the Aβ chaperone APOE in the AD brain and the lipids and Aβ released from damaged neurons (Guerreiro et al., 2013).”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The amyloid cascade hypothesis put forward in the 1990s proposes that misfolded and aggregated amyloid-beta (Aβ) protein triggers the pathological hallmarks of AD, such as neuronal cell death and dementia (Hardy and Allsop, 1991; Hardy and Higgins, 1992).”
BackgroundImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“In contrast, Aβ levels were markedly decreased in 3×Tg AD mice overexpressing IL-1β, highlighting that neuro-inflammatory cytokines affect AD (Heppner et al., 2015).”
BackgroundElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968 · cited 1×
“CSF1R is well-established as a critical surface receptor for microglia (Elmore et al., 2014).”
BackgroundNeuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“Targeting the physiological processing and inflammation involved in glia, cytokine release, and inflammasome formation is the best approach for cognitive disorders, including AD (Calsolaro and Edison, 2016; Ryan and Kelly, 2016; Toricelli et al., 2021).”
BackgroundSynaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715 · cited 1×
“Glia-derived TNF-α has been shown to regulate homeostatic synaptic scaling (Stellwagen and Malenka, 2006).”
BackgroundMicroglia Biology: One Century of Evolving Concepts
Prinz, M., Jung, S., & Priller, J. (2019) · Cell · doi:10.1016/j.cell.2019.08.053 · Cited by 1,525 · cited 1×
“By adopting different states in AD, microglia migrate to damage sites, secrete various inflammatory molecules, and phagocytose debris and aggregated proteins (Prinz et al., 2019).”
BackgroundNLRP3 inflammasome activation drives tau pathology
Ising, C., Venegas, C., Zhang, S., Scheiblich, H., Schmidt, S. V., Vieira-Saecker, A., Schwartz, S., Albasset, S., McManus, R. M., Tejera, D., et al. (2019) · Nature · doi:10.1038/s41586-019-1769-z · Cited by 1,487
Microglial control of astrocytes in response to microbial metabolites
Rothhammer, V., Borucki, D. M., Tjon, E. C., Takenaka, M. C., Chao, C.-C., Ardura-Fabregat, A., de Lima, K. A., Gutiérrez-Vázquez, C., Hewson, P., Staszewski, O., et al. (2018) · Nature · doi:10.1038/s41586-018-0119-x · Cited by 1,051 · cited 1×
“Ample evidence suggests that astrocytes are reactivated by microglia and play an essential role in neuroinflammatory and neurodegenerative processes in AD (Liddelow et al., 2017; Rothhammer et al., 2018).”
BackgroundARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012 · cited 1×
“Later, another R62H substitution in TREM2 was identified (Sims et al., 2017).”
BackgroundDisease-associated astrocytes in Alzheimer’s disease and aging
Habib, N., McCabe, C., Medina, S., Varshavsky, M., Kitsberg, D., Dvir-Szternfeld, R., Green, G., Dionne, D., Nguyen, L., Marshall, J. L., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0624-8 · Cited by 1,009
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0815-6 · Cited by 1,001 · cited 1×
“The pathological response of human astrocytes includes reactive astrogliosis and astroglia atrophy (Johnson et al., 2020).”
BackgroundMicroglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease
Venegas, C., Kumar, S., Franklin, B. S., Dierkes, T., Brinkschulte, R., Tejera, D., Vieira-Saecker, A., Schwartz, S., Santarelli, F., Kummer, M. P., et al. (2017) · Nature · doi:10.1038/nature25158 · Cited by 983 · cited 2×
“This means that the ‘activation’ of microglia has both beneficial and detrimental roles in the pathogenesis of AD (Venegas et al., 2017; Zhao et al., 2018).”
BackgroundTREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge
Nugent, A. A., Lin, K., van Lengerich, B., Lianoglou, S., Przybyla, L., Davis, S. S., Llapashtica, C., Wang, J., Kim, D. J., Xia, D., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.007 · Cited by 798
Microglia Heterogeneity in the Single-Cell Era
Masuda, T., Sankowski, R., Staszewski, O., & Prinz, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.010 · Cited by 784 · cited 2×
“The implementation of single-cell RNA sequencing and cytometry by time-of-flight mass spectrometry has demonstrated distinct gene expression profiles of microglia under different conditions, providing a high-resolution view of the developmental and spatial heterogeneity of microglia across multiple brain regions (Masu…”
BackgroundTREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Self-citationTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“One of the bestcharacterized AD-related PRRs is TREM2 (Ulland and Colonna, 2018).”
BackgroundHopperton, K. E., Mohammad, D., Trépanier, M. O., Giuliano, V, & Bazinet, R. P. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.246 · Cited by 622 · cited 1×
“These PRRs, including TREM2, RAGE, sialic acidbinding immunoglobulin-like lectin (Siglec) 3 (also known as CD33), Siglec 2 (also known as CD22), dectin-1 (also known as CLEC7A), and the complement receptors C1qR and CR3, enable microglia to sense and respond to various immunostimulatory signals in the brain (Deczkowsk…”
BackgroundNutrition and prevention of cognitive impairment
Scarmeas, N., Anastasiou, C. A., & Yannakoulia, M. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30338-7 · Cited by 612 · cited 1×
“The Multicultural Healthy Diet (NCT03240406) should help formulate specific guidelines based on foods with anti-inflammatory properties for the prevention of cognitive impairment (Scarmeas et al., 2018).”
BackgroundType I interferon response drives neuroinflammation and synapse loss in Alzheimer disease
Roy, E. R., Wang, B., Wan, Y.-W., Chiu, G., Cole, A., Yin, Z., Propson, N. E., Xu, Y., Jankowsky, J. L., Liu, Z., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133737 · Cited by 563
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200785 · Cited by 549
Hamelin, L., Lagarde, J., Dorothée, G., Leroy, C., Labit, M., Comley, R. A., de Souza, L. C., Corne, H., Dauphinot, L., Bertoux, M., et al. (2016) · Brain · doi:10.1093/brain/aww017 · Cited by 519
Dagher, N. N., Najafi, A. R., Kayala, K. M. N., Elmore, M. R. P., White, T. E., Medeiros, R., West, B. L., & Green, K. N. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0366-9 · Cited by 505 · cited 1×
“CSF1R inhibitors can suppress neuritic plaque accumulation, dendritic spine loss, neuroinflammation, and improve cognition in different AD mice models (Dagher et al., 2015; Sosna et al., 2018).”
BackgroundIntrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 1×
“Interestingly, higher CSF TNF-α levels have been found in individuals with AD, while individuals with mild cognitive impairment and high levels of TNF-α in the CSF are more likely to develop AD (Tarkowski et al., 2003).”
BackgroundOlabarria, M., Noristani, H. N., Verkhratsky, A., & Rodríguez, J. J. (2010) · Glia · doi:10.1002/glia.20967 · Cited by 499 · cited 1×
“Interestingly, several studies have shown that Aβ plaques surrounding astrocytes exhibit a reactive phenotype, even though atrophic astrocytes are not related to senile plaques (Olabarria et al., 2010; Beauquis et al., 2013).”
BackgroundNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease
Saresella, M., La Rosa, F., Piancone, F., Zoppis, M., Marventano, I., Calabrese, E., Rainone, V., Nemni, R., Mancuso, R., & Clerici, M. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0088-1 · Cited by 489
Elusive roles for reactive astrocytes in neurodegenerative diseases
Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453 · cited 4×
“…signaling pathways (Butchi et al., 2010; Schachtrup et al., 2010; Gorina et al., 2011), such as the NF-κB pathway (Akama et al., 1998), MAPK pathway (Agusti et al., 2011), the JAK/STAT3 pathway (Ben Haim et al., 2015a, b), and the calcineurin pathway (Furman and Norris, 2014; Table 1).”
BackgroundInfluentialLai, K. S. P., Liu, C. S., Rau, A., Lanctôt, K. L., Köhler, C. A., Pakosh, M., Carvalho, A. F., & Herrmann, N. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316201 · Cited by 433
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline
vom Berg, J., Prokop, S., Miller, K. R., Obst, J., Kälin, R. E., Lopategui-Cabezas, I., Wegner, A., Mair, F., Schipke, C. G., Peters, O., et al. (2012) · Nature Medicine · doi:10.1038/nm.2965 · Cited by 416
TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1
Peng, Q., Malhotra, S., Torchia, J. A., Kerr, W. G., Coggeshall, K. M., & Humphrey, M. B. (2010) · Science Signaling · doi:10.1126/scisignal.2000500 · Cited by 413
Regulation of Microglial Proliferation during Chronic Neurodegeneration
Gómez-Nicola, D., Fransen, N. L., Suzzi, S., & Perry, V. H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4440-12.2013 · Cited by 407
Sosna, J., Philipp, S., Albay, R., Reyes-Ruiz, J. M., Baglietto-Vargas, D., LaFerla, F. M., & Glabe, C. G. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0244-x · Cited by 406 · cited 1×
“CSF1R inhibitors can suppress neuritic plaque accumulation, dendritic spine loss, neuroinflammation, and improve cognition in different AD mice models (Dagher et al., 2015; Sosna et al., 2018).”
BackgroundInduction of Glial Fibrillary Acidic Protein Expression in Astrocytes by Nitric Oxide
Brahmachari, S., Fung, Y. K., & Pahan, K. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5480-05.2006 · Cited by 390
TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease
Griciuc, A., Patel, S., Federico, A. N., Choi, S. H., Innes, B. J., Oram, M. K., Cereghetti, G., McGinty, D., Anselmo, A., Sadreyev, R. I., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.06.010 · Cited by 378 · cited 1×
“The binding of Siglec 3 to TREM2 has been shown to yield an inhibitory effect on TREM2 signaling (Griciuc et al., 2019).”
BackgroundZhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371 · cited 1×
“Accordingly, levels of soluble TREM2 has been suggested as a possible AD biomarker (Zhong et al., 2019).”
BackgroundIL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
Fu, A. K. Y., Hung, K.-W., Yuen, M. Y. F., Zhou, X., Mak, D. S. Y., Chan, I. C. W., Cheung, T. H., Zhang, B., Fu, W.-Y., Liew, F. Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604032113 · Cited by 369 · cited 2×
“Cytokines and Immune Signaling in Alzheimer’s Disease Over the years, many natural immune cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-10, IL-12, IL-18, IL-23, IL-33, IL-34, IL-1β, and type I interferon, have been suggested to be tightly related to diverse AD processes (Mizuno et al., 2011; Bha…”
BackgroundYamamoto, M., Kiyota, T., Horiba, M., Buescher, J. L., Walsh, S. M., Gendelman, H. E., & Ikezu, T. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060378 · Cited by 367
Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology
Guillot-Sestier, M.-V., Doty, K. R., Gate, D., Rodriguez, J., Leung, B. P., Rezai-Zadeh, K., & Town, T. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.068 · Cited by 363
Yang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-16.2016 · Cited by 347
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337 · cited 1×
“In addition, supplementation of soluble TREM2 into 5×FAD mouse brains improves Aβ clearance, promotes microglia proliferation, and prevents further neurotic dystrophy (Wang et al., 2015; Piccio et al., 2016).”
BackgroundBen Haim, L., Ceyzériat, K., Carrillo-de Sauvage, M. A., Aubry, F., Auregan, G., Guillermier, M., Ruiz, M., Petit, F., Houitte, D., Faivre, E., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3516-14.2015 · Cited by 335
Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region
Schlepckow, K., Monroe, K. M., Kleinberger, G., Cantuti‐Castelvetri, L., Parhizkar, S., Xia, D., Willem, M., Werner, G., Pettkus, N., Brunner, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911227 · Cited by 324 · cited 1×
“Another antibody clone, 4D9, has been reported to be a very potent binder to the extracellular domain of TREM2 (Schlepckow et al., 2020), causing selective reduction of soluble oligomers in an APP knock-in mouse model.”
BackgroundCoding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314 · cited 1×
“Furthermore, many other TREM2 variants, such as D87N, L211P, T96K, and H157Y, have been associated with AD (Jin et al., 2014; Ghani et al., 2016; Jiang et al., 2016).”
BackgroundTargeting Astrocytes Ameliorates Neurologic Changes in a Mouse Model of Alzheimer's Disease
Furman, J. L., Sama, D. M., Gant, J. C., Beckett, T. L., Murphy, M. P., Bachstetter, A. D., Van Eldik, L. J., & Norris, C. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2323-12.2012 · Cited by 313
Microglial TREM2/DAP12 signaling: a double-edged sword in neural diseases
Konishi, H., & Kiyama, H. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00206 · Cited by 300
Improved tools to study astrocytes
Yu, X., Nagai, J., & Khakh, B. S. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0264-8 · Cited by 298 · cited 1×
“Astrocytes produce neurotransmitters and stimulate synaptogenesis and synaptic neurotransmission, forming part of the blood-brain barrier (Yu et al., 2020).”
BackgroundActivation of Microglia by Amyloid β Requires P2X7 Receptor Expression
Sanz, J. M., Chiozzi, P., Ferrari, D., Colaianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., & Di Virgilio, F. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803612 · Cited by 293 · cited 1×
“Moreover, Aβ can induce accumulation of IL-1β in microglia from wild-type but not from P2X7-deleted mice (Sanz et al., 2009).”
BackgroundSuárez-Calvet, M., Araque Caballero, M. Á., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., Levin, J., Danek, A., Ewers, M., Haass, C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1767 · Cited by 272 · cited 1×
“A Dominantly Inherited Alzheimer Network study involving 16 centers worldwide discovered that soluble TREM2 in CSF is produced in AD in a disease progression-dependent manner (Suarez-Calvet et al., 2016).”
BackgroundNeurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation
Schwartz, M., & Deczkowska, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.001 · Cited by 246 · cited 2×
“It is well established that, in the CNS, microglia and astrocytes are the predominant mediators of inflammation (Hamelin et al., 2016; Schwartz and Deczkowska, 2016; Alves et al., 2017; Daria et al., 2017).”
BackgroundA20 critically controls microglia activation and inhibits inflammasome-dependent neuroinflammation
Voet, S., Mc Guire, C., Hagemeyer, N., Martens, A., Schroeder, A., Wieghofer, P., Daems, C., Staszewski, O., Vande Walle, L., Jordao, M. J. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04376-5 · Cited by 227 · cited 1×
“Furthermore, overwhelming evidence suggests that ablation of NLRP3 inflammasomes decreases Aβ deposition and attenuates long-term potentiation and spatial memory deficits in APP/ PS1 mice (Mitroulis et al., 2010; Goldmann et al., 2013; Pennisi et al., 2017; Voet et al., 2018).”
BackgroundTaipa, R., das Neves, S. P., Sousa, A. L., Fernandes, J., Pinto, C., Correia, A. P., Santos, E., Pinto, P. S., Carneiro, P., Costa, P., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.12.019 · Cited by 205 · cited 1×
“Moreover, p40 ablation in APP/PS1 mice mitigates Aβ levels and cognitive deficits (Taipa et al., 2019).”
BackgroundTranscriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease
Chapuis, J., Hot, D., Hansmannel, F., Kerdraon, O., Ferreira, S., Hubans, C., Maurage, C. A., Huot, L., Bensemain, F., Laumet, G., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.10 · Cited by 201 · cited 1×
“Moreover, intraperitoneal injection of IL-33 into APP/PS1 AD mice could decrease Aβ levels, improve contextual memory, and restore longterm potentiation deficiency (Chapuis et al., 2009).”
BackgroundTreatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis
Chou, R. C., Kane, M., Ghimire, S., Gautam, S., & Gui, J. (2016) · CNS Drugs · doi:10.1007/s40263-016-0374-z · Cited by 194 · cited 1×
“Studies have also found that anti-TNF therapy for arthritis was associated with a lower risk of AD, suggesting its potential for AD treatment (Camargo et al., 2015; Chou et al., 2016).”
Backgroundβ-Amyloid Clustering around ASC Fibrils Boosts Its Toxicity in Microglia
Friker, L. L., Scheiblich, H., Hochheiser, I. V., Brinkschulte, R., Riedel, D., Latz, E., Geyer, M., & Heneka, M. T. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.025 · Cited by 191 · cited 1×
“Pyroptotic microglia release ASC that can be functionally built into the neighboring microglia NLRP3 inflammasome (Friker et al., 2020).”
BackgroundNew role of P2X7 receptor in an Alzheimer’s disease mouse model
Martin, E., Amar, M., Dalle, C., Youssef, I., Boucher, C., Le Duigou, C., Brückner, M., Prigent, A., Sazdovitch, V., Halle, A., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0108-3 · Cited by 187 · cited 1×
“release of the chemokine ligand CCL3, associated with pathogenic CD8 T cell recruitment in AD animal models (Martin et al., 2019).”
BackgroundMicroglial immune checkpoint mechanisms
Deczkowska, A., Amit, I., & Schwartz, M. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0145-x · Cited by 185 · cited 2×
“These PRRs, including TREM2, RAGE, sialic acidbinding immunoglobulin-like lectin (Siglec) 3 (also known as CD33), Siglec 2 (also known as CD22), dectin-1 (also known as CLEC7A), and the complement receptors C1qR and CR3, enable microglia to sense and respond to various immunostimulatory signals in the brain (Deczkowsk…”
BackgroundShieh, C., Heinrich, A., Serchov, T., van Calker, D., & Biber, K. (2014) · Glia · doi:10.1002/glia.22628 · Cited by 179
Young microglia restore amyloid plaque clearance of aged microglia
Daria, A., Colombo, A., Llovera, G., Hampel, H., Willem, M., Liesz, A., Haass, C., & Tahirovic, S. (2017) · The EMBO Journal · doi:10.15252/embj.201694591 · Cited by 174
Dourlen, P., Kilinc, D., Malmanche, N., Chapuis, J., & Lambert, J.-C. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02004-0 · Cited by 168 · cited 1×
“The new avenues on microglia, astrocytes, inflammatory cytokines, and inflammasomes have generated a burgeoning field in AD treatment research (Dourlen et al., 2019).”
BackgroundHarris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
Kulijewicz‐Nawrot, M., Verkhratsky, A., Chvátal, A., Syková, E., & Rodríguez, J. J. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2012.01536.x · Cited by 160 · cited 1×
“Atrophic astrocytes can be observed in the early stages of AD animal models, which may affect synaptic connectivity because of reduced astrocyte arborization, leading to progressive cognitive deterioration (Yeh et al., 2011; Kulijewicz-Nawrot et al., 2012).”
BackgroundMizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., & Suzumura, A. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.06.011 · Cited by 159 · cited 1×
“…(IL)-10, IL-12, IL-18, IL-23, IL-33, IL-34, IL-1β, and type I interferon, have been suggested to be tightly related to diverse AD processes (Mizuno et al., 2011; Bhaskar et al., 2014; Tan et al., 2014; Guillot-Sestier et al., 2015; Fu et al., 2016; Taylor et al., 2018; Thawkar and Kaur,…”
BackgroundInflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease
Pennisi, M., Crupi, R., Di Paola, R., Ontario, M. L., Bella, R., Calabrese, E. J., Crea, R., Cuzzocrea, S., & Calabrese, V. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23986 · Cited by 157 · cited 1×
“Furthermore, overwhelming evidence suggests that ablation of NLRP3 inflammasomes decreases Aβ deposition and attenuates long-term potentiation and spatial memory deficits in APP/ PS1 mice (Mitroulis et al., 2010; Goldmann et al., 2013; Pennisi et al., 2017; Voet et al., 2018).”
BackgroundInflammatory markers in AD and MCI patients with different biomarker profiles
Schuitemaker, A., Dik, M. G., Veerhuis, R., Scheltens, P., Schoonenboom, N. S. M., Hack, C. E., Blankenstein, M. A., & Jonker, C. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.01.014 · Cited by 149
Melo, H. M., Seixas da Silva, G. D. S., Sant’Ana, M. R., Teixeira, C. V. L., Clarke, J. R., Miya Coreixas, V. S., de Melo, B. C., Fortuna, J. T. S., Forny-Germano, L., Ledo, J. H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.072 · Cited by 140
Hall, B., Mak, E., Cervenka, S., Aigbirhio, F. I., Rowe, J. B., & O’Brien, J. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.002 · Cited by 132
Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo
Chakrabarty, P., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-16 · Cited by 117
A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese
Jiang, T., Tan, L., Chen, Q., Tan, M.-S., Zhou, J.-S., Zhu, X.-C., Lu, H., Wang, H.-F., Zhang, Y.-D., & Yu, J.-T. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.023 · Cited by 110
Butchi, N. B., Du, M., & Peterson, K. E. (2010) · Glia · doi:10.1002/glia.20952 · Cited by 109 · cited 1×
“The reactivity of astrocytes can be initiated and modulated by multiple inflammation-related signaling pathways (Butchi et al., 2010; Schachtrup et al., 2010; Gorina et al., 2011), such as the NF-κB pathway (Akama et al.”
BackgroundViel, T., Toricelli, M., Pereira, A. R., Souza Abrao, G., Malerba, H., Maia, J., & Buck, H. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.286952 · Cited by 102
Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study
Brosseron, F., Kolbe, C., Santarelli, F., Carvalho, S., Antonell, A., Castro‐Gomez, S., Tacik, P., Namasivayam, A. A., Mangone, G., Schneider, R., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.07.018 · Cited by 47 · cited 1×
“Numerous studies have focused on Aβ generation and processing, but the lack of solid clinical results has forced us to look at other factors (Brosseron et al., 2020; Nugent et al., 2020).”
Background
Cited by
Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins
Chadarevian, J. P., Davtyan, H., Chadarevian, A. L., Nguyen, J., Capocchi, J. K., Le, L., Escobar, A., Chadarevian, T., Mansour, K., Deynega, E., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.009 · Cited by 60
The emerging double-edged sword role of exosomes in Alzheimer’s disease
Liang, T., Wu, Z., Li, J., Wu, S., Shi, W., & Wang, L. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1209115 · Cited by 37
Zhang, L., Lin, J., Xiang, K., Shi, T., & Guo, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.10.033 · Cited by 26
Wei, Z., Dong, X., & Sun, Y. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c10137 · Cited by 5
Metadata
- Authors
- Liu, Y., Si, Z.-Z., Zou, C.-J., Mei, X., Li, X.-F., Luo, H., Shen, Y., Hu, J., Li, X.-X., & Wu, L.
- Venue
- Neural Regeneration Research
- Publisher
- Medknow
- Published
- 2023
- Volume
- 18
- Issue
- 4
- Pages
- 708
- ISSN
- 1673-5374 (ISSN-L)
- OpenAlex
- W4296955690
- Cited by
- 182
- References
- 78
- FWCI
- 10.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.